CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence ...

Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Splitting shares won't double your money. When a stock splits, shareholders each get more shares. The price per share falls proportionally.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.0, a high estimate of $6.00, and a low estimate of $4.00. Witnessing a positive shift, the current average ...

What you need to know about Ark Invest, an active ETF firm led by Cathie Wood that invests in disruptive, high-growth tech ...

Infectious disease testmaker OraSure Technologies is coming under additional pressure from investors, according to ...

Discover how Simplify Health Care ETF outperforms with active healthcare stock selection, offering alpha where others see ...

Epicrispr Biotechnologies CEO Amber Salzman, Ph.D. offers up four imperatives for industry leaders working to develop tomorrows genetic therapies.

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...